|
|
PMPA
is a new type of nucleotide reverse transcriptase inhibitor
(NRTI) that has exhibited potent antiretroviral action.
In earlier studies, greater than one log drops in plasma
HIV levels were seen in the highest dose groups. |
|
Objective
|
To
determine whether PMPA is safe and effective as an antiretroviral
agent. |
|
|
Volunteers
are assigned to one of three dosing regimens of PMPA
(75 mg, 150 mg or 300 mg, once daily) or placebo, in
addition to
their current antiretroviral therapy.
|
|
Inclusion
Criteria
|
- HIV-positive
male or female 18-65 y.o.
- Viral
load greater than 400 and 100,000 copies/mL
- On
stable antiretroviral therapy for at least 8 weeks
prior to trial entry
- Normal
kidney and liver function
|
|
Status
__
|
Enrollment completed; study ongoing
--
|
|
|
|
We
encourage participation by women and people of color.
This
ad was reviewed and approved by the AIDS Research Alliance
Institutional Review Board in January, 2001.
|
